Bioavailability of phenolics from olive leaf extract.

GROUP 1:

1. Premenopausal women between 18 and 75 years old;

2. No history of hormone-related disorders or surgical interventions affecting female hormone balance (e.g. ovariectomy);

3. Premenopausal women should be on monophasic oral anti conception and the test day should not be in the pause week or in the first 3 days of pill use;

4. Only non‐smoking individuals can participate, who did not smoke during at least 6 months before the start of the study;

5. The participants are capable and willing to sign the Informed Consent Form at voluntary basis, after having received detailed information;

6. The volunteers are considered healthy based on their medical history as questioned by the investigator;

7. The volunteers do not intend to become pregnant prior to or during the study.



GROUP 2:

1. Postmenopausal women (between 18 and 75 years old) as determined by the principal investigator. The participants should be at least 2 years post menopausal;

2. During the last ten days prior to the test day, the subjects are not allowed to use hormones, medicinal products, food supplements, anti-osteoporosis medication or vitamins that can influence bone metabolism or the test product. Subjects are allowed to continue chronic use of other drugs, which do not influence the outcome of the study;

3. Only non‐smoking individuals can participate, who did not smoke during at least 6 months before the start of the study;

4. The participants are capable and willing to sign the Informed Consent Form at voluntary basis, after having received detailed information.

1. Clinically significant abnormal liver functioning (serum alanine and aspartate aminotransferase);

2. Clinically significant abnormal serum creatinin;

3. Abnormal BMI (i.e. lower than 18 or higher than 30);

4. Use of concomitant medications or supplements;

5. Blood donation during the last 4 weeks prior to the first dosing till 4 weeks after the last dosing.